762 related articles for article (PubMed ID: 19060118)
1. Role of the amiloride-sensitive epithelial Na+ channel in the pathogenesis and as a therapeutic target for cystic fibrosis lung disease.
Mall MA
Exp Physiol; 2009 Feb; 94(2):171-4. PubMed ID: 19060118
[TBL] [Abstract][Full Text] [Related]
2. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice.
Mall M; Grubb BR; Harkema JR; O'Neal WK; Boucher RC
Nat Med; 2004 May; 10(5):487-93. PubMed ID: 15077107
[TBL] [Abstract][Full Text] [Related]
3. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice.
Zhou Z; Treis D; Schubert SC; Harm M; Schatterny J; Hirtz S; Duerr J; Boucher RC; Mall MA
Am J Respir Crit Care Med; 2008 Dec; 178(12):1245-56. PubMed ID: 18849497
[TBL] [Abstract][Full Text] [Related]
4. The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease.
Zhou Z; Duerr J; Johannesson B; Schubert SC; Treis D; Harm M; Graeber SY; Dalpke A; Schultz C; Mall MA
J Cyst Fibros; 2011 Jun; 10 Suppl 2():S172-82. PubMed ID: 21658636
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease.
Hirsh AJ; Sabater JR; Zamurs A; Smith RT; Paradiso AM; Hopkins S; Abraham WM; Boucher RC
J Pharmacol Exp Ther; 2004 Dec; 311(3):929-38. PubMed ID: 15273255
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease.
Hirsh AJ; Zhang J; Zamurs A; Fleegle J; Thelin WR; Caldwell RA; Sabater JR; Abraham WM; Donowitz M; Cha B; Johnson KB; St George JA; Johnson MR; Boucher RC
J Pharmacol Exp Ther; 2008 Apr; 325(1):77-88. PubMed ID: 18218832
[TBL] [Abstract][Full Text] [Related]
7. Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells.
Noël S; Wilke M; Bot AG; De Jonge HR; Becq F
J Pharmacol Exp Ther; 2008 Jun; 325(3):1016-23. PubMed ID: 18309088
[TBL] [Abstract][Full Text] [Related]
8. Functional interaction of CFTR and ENaC in sweat glands.
Reddy MM; Quinton PM
Pflugers Arch; 2003 Jan; 445(4):499-503. PubMed ID: 12548396
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of amiloride-sensitive Na(+) absorption by activation of CFTR in mouse endometrial epithelium.
Chan LN; Wang XF; Tsang LL; So SC; Chung YW; Liu CQ; Chan HC
Pflugers Arch; 2001; 443 Suppl 1():S132-6. PubMed ID: 11845319
[TBL] [Abstract][Full Text] [Related]
10. Specific inhibition of epithelial Na+ channels by antisense oligonucleotides for the treatment of Na+ hyperabsorption in cystic fibrosis.
Sobczak K; Segal A; Bangel-Ruland N; Semmler J; Van Driessche W; Lindemann H; Heermann R; Weber WM
J Gene Med; 2009 Sep; 11(9):813-23. PubMed ID: 19533590
[TBL] [Abstract][Full Text] [Related]
11. Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway.
Zhang LN; Karp P; Gerard CJ; Pastor E; Laux D; Munson K; Yan Z; Liu X; Godwin S; Thomas CP; Zabner J; Shi H; Caldwell CW; Peluso R; Carter B; Engelhardt JF
Mol Ther; 2004 Dec; 10(6):990-1002. PubMed ID: 15564131
[TBL] [Abstract][Full Text] [Related]
12. Cystic fibrosis: a disease of vulnerability to airway surface dehydration.
Boucher RC
Trends Mol Med; 2007 Jun; 13(6):231-40. PubMed ID: 17524805
[TBL] [Abstract][Full Text] [Related]
13. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.
Moore PJ; Tarran R
Expert Opin Ther Targets; 2018 Aug; 22(8):687-701. PubMed ID: 30028216
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the amiloride-sensitive epithelial sodium channel in patients with cystic fibrosis-like disease.
Azad AK; Rauh R; Vermeulen F; Jaspers M; Korbmacher J; Boissier B; Bassinet L; Fichou Y; des Georges M; Stanke F; De Boeck K; Dupont L; Balascáková M; Hjelte L; Lebecque P; Radojkovic D; Castellani C; Schwartz M; Stuhrmann M; Schwarz M; Skalicka V; de Monestrol I; Girodon E; Férec C; Claustres M; Tümmler B; Cassiman JJ; Korbmacher C; Cuppens H
Hum Mutat; 2009 Jul; 30(7):1093-103. PubMed ID: 19462466
[TBL] [Abstract][Full Text] [Related]
15. Effects of purinergic stimulation, CFTR and osmotic stress on amiloride-sensitive Na+ transport in epithelia and Xenopus oocytes.
Schreiber R; König J; Sun J; Markovich D; Kunzelmann K
J Membr Biol; 2003 Mar; 192(2):101-10. PubMed ID: 12682798
[TBL] [Abstract][Full Text] [Related]
16. Expression of CFTR from a ciliated cell-specific promoter is ineffective at correcting nasal potential difference in CF mice.
Ostrowski LE; Yin W; Diggs PS; Rogers TD; O'Neal WK; Grubb BR
Gene Ther; 2007 Oct; 14(20):1492-501. PubMed ID: 17637798
[TBL] [Abstract][Full Text] [Related]
17. The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways.
Mall M; Bleich M; Greger R; Schreiber R; Kunzelmann K
J Clin Invest; 1998 Jul; 102(1):15-21. PubMed ID: 9649552
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells.
Mroz MS; Harvey BJ
Steroids; 2019 Nov; 151():108461. PubMed ID: 31344409
[TBL] [Abstract][Full Text] [Related]
19. [Early bronchial inflammation in cystic fibrosis].
Puchelle E
J Soc Biol; 2002; 196(1):29-35. PubMed ID: 12134630
[TBL] [Abstract][Full Text] [Related]
20. Morphological analysis of the trachea and pattern of breathing in βENaC-Tg mice.
Bonora M; Riffault L; Marie S; Mall M; Clement A; Tabary O
Respir Physiol Neurobiol; 2011 Sep; 178(2):346-8. PubMed ID: 21700000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
